Fluoroquinolone resistance in multidrug-resistant tuberculosis patients

참고문헌 (9)

1. World Health Organization, "Global Tuberculosis Report 2018" (2018), World Health Organization
2. Lee M, "Multidrug-resistant tuberculosis in South Korea: a retrospective analysis of national registry data in 2011-15", Int J Tuberc Lung Dis (2019)
3. Kwak N, "Long-term survival of patients with multidrug-resistant tuberculosis according to treatment outcomes", Am J Infect Control, 44, pp.843~845 (2016)
4. 김현석, "Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study", The Korean Journal of Internal Medicine, 34(2), pp.344~352 (2019), 대한내과학회[DOI]
5. Caminero JA, "Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis", Lancet Infect Dis, 10, pp.621~629 (2010)
6. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017, "Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis : an individual patient data meta-analysis", Lancet, 392, pp.821~834 (2018)
7. World Health Organization, "WHO Treatment Guidelines for Multidrug-and Rifampicin-Resistant Tuberculosis 2018", World Health Organization, ~ (2018)
8. Pantel A, "Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis", Antimicrob Agents Chemother, 56, pp.1990~1996 (2012)
9. Cegielski JP, "Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance", Clin Infect Dis, 62, pp.418~430 (2016)

관련 논문AI추천